admin – Page 7365 – Get News Story

Systemic Sclerosis Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Certa Therapeutics, Eicos, Sanofi, Bayer, Janssen, Gesynta,, Pfizer, Seagen, CSL

“Delveinsight Business Research LLP”

As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Systemic Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Systemic Sclerosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Systemic Sclerosis Market.

The Systemic Sclerosis Pipeline report embraces in-depth commercial, regulatory, and Systemic Sclerosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Systemic Sclerosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Systemic Sclerosis Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the emerging therapies for Systemic Sclerosis treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Systemic Sclerosis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Systemic Sclerosis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Systemic Sclerosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Systemic Sclerosis therapeutic market.

Systemic Sclerosis Therapeutics Landscape

Several prominent pharma and biotech companies are actively involved in developing therapies for Systemic Sclerosis, Among these key players, Eicos Sciences stands out for advancing its Systemic Sclerosis drug candidates to the most advanced stage of clinical trials, specifically the Phase III stage. This significant progress underscores the collective commitment within the pharmaceutical industry to address the challenges posed by Systemic Sclerosis and emphasizes Eicos Sciences’ dedication to advancing innovative treatments for individuals affected by this complex and debilitating condition.

Systemic Sclerosis Companies Actively Working in the Therapeutic Market Include:

In the vast landscape of the Systemic Sclerosis therapeutics market, numerous pharma and biotech giants are making significant contributions. Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, and BriaCell Therapeutics are among the key players pushing the boundaries of innovation and striving to address the unmet medical needs in the Systemic Sclerosis therapeutics landscape.

Emerging and Marketed Systemic Sclerosis Drugs Covered in the Report Include:

Iloprost: Eicos Sciences
ECCS 50: Cytori therapeutics
Lenabasum (JBT-101): Corbus Pharmaceuticals
EHP-101: Emerald Health Pharmaceuticals

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Systemic Sclerosis Companies Working in the Market:

https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight

Analysis of Emerging Systemic Sclerosis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates

Route of Administration

Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn How the Systemic Sclerosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Systemic Sclerosis Treatment Patterns

4. Systemic Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Systemic Sclerosis Late Stage Products (Phase-III)

7. Systemic Sclerosis Mid-Stage Products (Phase-II)

8. Systemic Sclerosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Systemic Sclerosis Discontinued Products

13. Systemic Sclerosis Product Profiles

14. Major Systemic Sclerosis Companies in the Market

15. Key Products in the Systemic Sclerosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Systemic Sclerosis Unmet Needs

18. Systemic Sclerosis Future Perspectives

19. Systemic Sclerosis Analyst Review

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Portal Hypertension Market

“Portal Hypertension Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Portal Hypertension market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Portal Hypertension market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Sclerosis Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Certa Therapeutics, Eicos, Sanofi, Bayer, Janssen, Gesynta,, Pfizer, Seagen, CSL

Uncomplicated Urinary Tract Infections (UTI) Market to Observe Stunning Growth During the Forecast Period (2023-32) – DelveInsight | GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen, Fimbrion

“Delveinsight Business Research LLP”

DelveInsight’s “Uncomplicated Urinary Tract Infections (UTI) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Uncomplicated Urinary Tract Infections market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Uncomplicated Urinary Tract Infections drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Uncomplicated Urinary Tract Infections treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Uncomplicated Urinary Tract Infections (UTI): An Overview

Urinary tract infection (UTI) is the most common bacterial infection caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. A urinary tract infection can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. They are classified as either complicated or uncomplicated.

Uncomplicated urinary tract infections typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. Complicated urinary tract infection is associated with factors that compromise the urinary tract or host defense.

Uncomplicated Urinary Tract Infections (UTI) Market Key Facts

In 2021, the total market size of Uncomplicated Urinary Tract Infections was USD 927 million, which is expected to rise by 2032.
The total market size of Uncomplicated Urinary Tract Infections in the United States accounted for USD 590 million in 2021.
In EU5, the total market size of Uncomplicated Urinary Tract Infections was USD 228 million in 2021.
In Japan, the total market size of Uncomplicated Urinary Tract Infections was USD 110 million in 2021.
In the year 2021, total Diagnosed Cases of Uncomplicated Urinary Tract infections were 19,624 in the 7MM which is expected to grow during the study period, i.e., 2019–2032.
In the United States, the total occurrence-specific cases of uncomplicated urinary tract infections were 14,922 cases in the year 2021.
In the year 2021, the total occurrence-specific cases of uncomplicated urinary tract infection were 14,006 cases in EU-5. Italy recorded the highest number of occurrence-specific cases of uncomplicated urinary tract infections, followed by France and the United Kingdom.
In Japan, the total occurrence-specific cases of uncomplicated urinary tract infections were 6,753 cases in the year 2021.

Uncomplicated Urinary Tract Infections Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Uncomplicated Urinary Tract Infections pipeline therapies. It also thoroughly assesses the Uncomplicated Urinary Tract Infections market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Uncomplicated Urinary Tract Infections drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Uncomplicated Urinary Tract Infections Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Uncomplicated Urinary Tract Infections epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Uncomplicated Urinary Tract Infections epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Uncomplicated Urinary Tract Infections Epidemiology, Segmented as –

Total Occurrence-specific cases of Uncomplicated Urinary Tract Infection
Total Diagnosed Cases of Uncomplicated Urinary Tract Infection
Total Age-specific Cases of Uncomplicated Urinary Tract Infection
Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection

Uncomplicated Urinary Tract Infections Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Uncomplicated Urinary Tract Infections market or expected to be launched during the study period. The analysis covers the Uncomplicated Urinary Tract Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Uncomplicated Urinary Tract Infections drugs based on their sale and market share.

The report also covers the Uncomplicated Urinary Tract Infections pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Uncomplicated Urinary Tract Infections companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Uncomplicated Urinary Tract Infections Market Will Evolve and Grow by 2032 @

https://www.delveinsight.com/sample-request/uncomplicated-urinary-tract-infection-uuti-market

Uncomplicated Urinary Tract Infections Companies Actively Working in the Therapeutics Market Include

GlaxoSmithKline
Iterum Therapeutics
Inmunotek
Janssen Pharmaceuticals
Fimbrion Therapeutics

And Many More

Emerging and Marketed Uncomplicated Urinary Tract Infections Therapies Covered in the Report Include:

GSK2140944/Gepotidacin (GlaxoSmithKline)
Sulopenem Etzadroxil – Probenecid (Iterum Therapeutics)
Uromune/MV140 (Inmunotek)

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/uncomplicated-urinary-tract-infection-uuti-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Uncomplicated Urinary Tract Infections Competitive Intelligence Analysis

4. Uncomplicated Urinary Tract Infections Market Overview at a Glance

5. Uncomplicated Urinary Tract Infections Disease Background and Overview

6. Uncomplicated Urinary Tract Infections Patient Journey

7. Uncomplicated Urinary Tract Infections Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Uncomplicated Urinary Tract Infections Treatment Algorithm, Current Treatment, and Medical Practices

9. Uncomplicated Urinary Tract Infections Unmet Needs

10. Key Endpoints of Uncomplicated Urinary Tract Infections Treatment

11. Uncomplicated Urinary Tract Infections Marketed Therapies

12. Uncomplicated Urinary Tract Infections Emerging Drugs and Latest Therapeutic Advances

13. Uncomplicated Urinary Tract Infections Seven Major Market Analysis

14. Attribute Analysis

15. Uncomplicated Urinary Tract Infections Market Outlook (In US, EU5, and Japan)

16. Uncomplicated Urinary Tract Infections Companies Active in the Market

17. Uncomplicated Urinary Tract Infections Access and Reimbursement Overview

18. KOL Views on the Uncomplicated Urinary Tract Infections Market

19. Uncomplicated Urinary Tract Infections Market Drivers

20. Uncomplicated Urinary Tract Infections Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/uncomplicated-urinary-tract-infection-uuti-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

Pars Plantis Market

“Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Pars Plantis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Pars Plantis market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Uncomplicated Urinary Tract Infections (UTI) Market to Observe Stunning Growth During the Forecast Period (2023-32) – DelveInsight | GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen, Fimbrion

Sepsis Market to Grow Substantially During the Forecast Period (2023-2032) – DelveInsight | Vivacelle Bio, Inotrem, Enlivex, Adrenomed, Shionogi, ABIONYX, Revimmune, Baxter, BioMarck Pharma, AM-Pharma

“Delveinsight Business Research LLP”

DelveInsight’s “Sepsis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sepsis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Sepsis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Sepsis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Sepsis: An Overview

Sepsis is a life-threatening organ dysfunction that results from the body’s response to infection. If not recognized early and managed promptly, it can lead to septic shock, multiple organ failure, and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries, where it represents a major cause of maternal and neonatal morbidity and mortality.

Sepsis requires prompt recognition, appropriate antibiotics, careful hemodynamic support, and control of the source of infection. Sepsis can be the clinical manifestation of infections acquired both in the community setting and in health care facilities. Healthcare-associated infections are one of, if not the most frequent, type of adverse event to occur during care delivery and affect hundreds of millions of patients worldwide every year. Since these infections are often resistant to antibiotics, they can rapidly lead to deteriorating clinical conditions. The largest contributors to sepsis cases and sepsis-related mortality across all ages are diarrheal diseases and lower respiratory infections. However, non-communicable diseases are on the rise; one-third of sepsis cases and nearly half of all sepsis-related deaths are due to an underlying injury or chronic disease.

In 2022, the Sepsis Market Size in the 7MM was approximately USD 2800 Million, and it is further expected to increase by 2032. As per DelveInsight, the Sepsis Market is anticipated to evolve immensely in the coming years owing to the rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, intense research activities, and the launch of new therapies in the market.

Sepsis Market Key Facts

In 2022, the Sepsis Market Size in the 7MM was approximately USD 2800 Million, which is further expected to increase by 2032.
According to the DelveInsight epidemiology forecast model, in 2022, there were 3,543,000+ cases of sepsis recorded in the 7MM, which is expected to increase by 2032.
Among the 7MM cases, the United States accounted for the maximum share of the Sepsis population with a 55% share in its bucket, making up 1,938,855 cases in 2022.
In 2022, there were 1,210,000+ cases of sepsis recorded in EU4 and the UK, which are expected to increase by 2032. Of all the EU countries, Germany accounted for the maximum share of the Sepsis population, with 322,000+ cases in 2022.
Assessments show that in Japan there were 394,000+ incident cases of Sepsis. The epidemiology figures show that Japan’s epidemiology was 11% of the total 7MM patient pool in 2022.

Sepsis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Sepsis pipeline therapies. It also thoroughly assesses the Sepsis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Sepsis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Sepsis Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Sepsis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Sepsis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Sepsis Epidemiology, Segmented as –

Sepsis Gender-Specific Incident Cases
Total Sepsis Incident Cases
Sepsis Severity Specific Incident Cases
Sepsis Treatable Cases, Sepsis Origin
Specific Incident Cases

Sepsis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Sepsis market or expected to be launched during the study period. The analysis covers the Sepsis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Sepsis drugs based on their sale and market share.

The report also covers the Sepsis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Sepsis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Sepsis Market Will Evolve and Grow by 2032:

https://www.delveinsight.com/sample-request/sepsis-market

Sepsis Therapeutics Analysis

Sepsis is a complex disease, that not only involves a wide array of causative agents but also results in different individual immune responses, causing various single or multiple organ dysfunctions. Treatment for sepsis varies, depending on the site and the cause of the initial infection, the organs affected, and the extent of any damage. Sepsis should be treated as a medical emergency and treated as quickly and efficiently as possible as soon as it has been identified. Sepsis treatment is examined under two categories, with appropriate antimicrobial treatment and all-purpose supporting treatment.

Several major pharma and biotech companies are developing therapies for Sepsis. Currently, SciClone Pharmaceuticals is leading the therapeutics market with its Sepsis drug candidates in the most advanced stage of clinical development.

In June 2023, Basilea Pharmaceuticals announced a study of phase 3 clinical trials for Ceftobiprole medocaril. This research will assess the safety, pharmacokinetics, and effectiveness of ceftobiprole in full-term and pre-term newborns as well as infants up to 3 months old who are affected by late-onset sepsis (LOS). Ceftobiprole, classified as a cephalosporin antibiotic, will be investigated for its potential use in treating LOS in this specific population.

In May 2023, Novartis Pharmaceuticals announced a study of phase 2 clinical trials for TIN816 70 mg lyophilisate powder. The aim of this research is to examine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of TIN816 and assess its safety and tolerability in adult patients admitted to an intensive care unit (ICU) who have been diagnosed with sepsis-related acute kidney injury (SA-AKI).

In June 2020, Ono Pharmaceutical announced that ONO received approval of Onoact (generic name: Landiolol hydrochloride) for Intravenous Infusion 50mg/150mg (“Onoact”), a short-acting selective β1 blocker for the additional indication of tachyarrhythmia (atrial fibrillation, atrial flutter, and sinus tachycardia) associated with sepsis for a partial change in the approved items of the manufacturing and marketing approval in Japan.

Sepsis Companies Actively Working in the Therapeutics Market Include

Some of the key companies in the Sepsis Therapeutics Market include La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.

Emerging and Marketed Sepsis Therapies Covered in the Report Include:

Adrecizumab: Adrenomed
Alirocumab: Regeneron/Sanofi
Allocetra: Enlivex Therapeutics
BIO-11006: BioMarck Pharmaceuticals
CER-001: ABIONYX Pharma
CYT107: Revimmune
Esmolol (esmolol hydrochloride): Baxter Healthcare Corporation
Fetroja/Fetcroja (Cefiderocol): Shionogi
M6229: Matisse Pharmaceuticals
Nangibotide (LR12): Inotrem
Onoact Injection (Landiolol hydrochloride): Ono Pharmaceutical
Recombinant human alkaline phosphatase: AM-Pharma
Recombinant human plasma gelsolin: BioAegis Therapeutics
Recomodulin (ART-123): Asahi Kasei Pharma Corp.
STC3141: CGE HealthcareGiapreza: La Jolla Pharmaceuticals
Thymosin alpha 1: SciClone Pharmaceuticals
Vasostrict: Par Pharmaceutical
VBI-S: Vivacelle Bio

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies:

https://www.delveinsight.com/sample-request/sepsis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Sepsis Competitive Intelligence Analysis

4. Sepsis Market Overview at a Glance

5. Sepsis Disease Background and Overview

6. Sepsis Patient Journey

7. Sepsis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Sepsis Treatment Algorithm, Current Treatment, and Medical Practices

9. Sepsis Unmet Needs

10. Key Endpoints of Sepsis Treatment

11. Sepsis Marketed Therapies

12. Sepsis Emerging Drugs and Latest Therapeutic Advances

13. Sepsis Seven Major Market Analysis

14. Attribute Analysis

15. Sepsis Market Outlook (In US, EU5, and Japan)

16. Sepsis Companies Active in the Market

17. Sepsis Access and Reimbursement Overview

18. KOL Views on the Sepsis Market

19. Sepsis Market Drivers

20. Sepsis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/sepsis-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

Osteochondromas Market

“Osteochondromas Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Osteochondromas market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Osteochondromas market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sepsis Market to Grow Substantially During the Forecast Period (2023-2032) – DelveInsight | Vivacelle Bio, Inotrem, Enlivex, Adrenomed, Shionogi, ABIONYX, Revimmune, Baxter, BioMarck Pharma, AM-Pharma

Social Anxiety Disorder Market to Accelerate Substantially During the Forecast Period (2023-2032) – DelveInsight | Key Companies – Vistagen Therapeutics, Bionomics, EmpowerPharm

“Delveinsight Business Research LLP”

DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Social Anxiety Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Social Anxiety Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Social Anxiety Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Social Anxiety Disorder: An Overview

Social Anxiety disorder (SAD), also called Social Phobia, is the most common mental health condition that causes extreme fear in social settings, and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, and attending social gatherings, which can also affect day-to-day activities.

Social anxiety disorder can make a person fear being judged or scrutinized by others. Patients may understand that their fears are irrational or unreasonable, but feel powerless to overcome them. Social anxiety is different from shyness, which is usually short-term and does not disrupt one’s life. Social anxiety is persistent and debilitating. It can affect one’s ability to work, attend school, and develop close relationships with people outside their family.

As per DelveInsight, the Social Anxiety Disorder Market is anticipated to evolve immensely in the coming years owing to the increase in R&D activity, the rising prevalent population in the 7MM, the expected commercial success of upcoming therapies, and the rise in healthcare spending across the world. The current pipeline of social anxiety disorder consists of PH94B (Vistagen Therapeutics), EPI-CBD-001 (EmpowerPharm), (Bionomics), and others.

Social Anxiety Disorder Market Key Facts

According to the National Institute of Mental Health (NIMH), about 1 in 8 people (12.1%) experience Social Anxiety Disorder at some time in their life and in a given year. According to the US National Institutes of Health (NIH), SAD is the third most common psychiatric condition after depression and substance abuse. Of adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment.
As per the Anxiety and Depression Association of America (ADAA) 2021, social anxiety disorder affects around 15 million adults or 6.8% of the US population. Many people are frequently misdiagnosed as a result of the disease. thirty-six of people with social anxiety disorder experience symptoms for 10 years or more before seeking care, according to a 2007 ADAA survey.
According to Cambridge University (2020), epidemiologic surveys conducted across Europe indicated that the lifetime prevalence of Social anxiety disorder in the general population is close to 7%.
According to the National Institute of Health and Care Excellence (NICE), the lifetime prevalence of social anxiety disorder is 12% in the UK population.
As per Judith et. Al. (2017), the lifetime prevalence of Social Anxiety Disorder in Germany is found to be around 12%.
As per Lisa Fritscher (2021), the prevalence of Taijin kyofusho (a Japanese form of Social Phobia) in Japan is between 10-20% in the general population, and it is somewhat more common in men than women.

Social Anxiety Disorder Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Social Anxiety Disorder pipeline therapies. It also thoroughly assesses the Social Anxiety Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Social Anxiety Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Social Anxiety Disorder Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Social Anxiety Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Social Anxiety Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Social Anxiety Disorder Epidemiology, Segmented as –

12-month Diagnosed Prevalent Cases of Social Anxiety Disorder
Gender-specific Cases of Social Anxiety Disorder
Age-specific Cases of Social Anxiety Disorder
Severity-Specific Cases of Social Anxiety Disorder
Total Treated Cases of Social Anxiety Disorder

Social Anxiety Disorder Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Social Anxiety Disorder market or expected to be launched during the study period. The analysis covers the Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Social Anxiety Disorder drugs based on their sale and market share.

The report also covers the Social Anxiety Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Social Anxiety Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Social Anxiety Disorder Market Will Evolve and Grow by 2032:

https://www.delveinsight.com/sample-request/social-anxiety-disorder-market

Social Anxiety Disorder Therapeutics Analysis

Patients who manage their symptoms with psychological and pharmacologic treatment are more likely to achieve continued symptom-improvement benefits. SAD is typically treated on a long-term basis using US FDA-approved antidepressants with a sluggish onset of action (weeks) and limited therapeutic effects, as well as benzodiazepines, which are not FDA-approved for the treatment of SAD but are recommended for off-label usage.

Once the patient attains the desired therapeutic response, the medication should be continued for at least 12 months in order to prevent relapse. Selective Serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), Gamma-aminobutyric acid (GABA), Beta-Blockers, and other anxiolytics are the standard drug classes used to treat SAD.

Social Anxiety Disorder Companies Actively Working in the Therapeutics Market Include

Vistagen Therapeutics
Bionomics
EmpowerPharm

And Many Others

Emerging and Marketed Social Anxiety Disorder Therapies Covered in the Report Include:

PH94B: Vistagen Therapeutics
BNC210: Bionomics
EPI-CBD-001: EmpowerPharm

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies:

https://www.delveinsight.com/sample-request/social-anxiety-disorder-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Social Anxiety Disorder Competitive Intelligence Analysis

4. Social Anxiety Disorder Market Overview at a Glance

5. Social Anxiety Disorder Disease Background and Overview

6. Social Anxiety Disorder Patient Journey

7. Social Anxiety Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Social Anxiety Disorder Treatment Algorithm, Current Treatment, and Medical Practices

9. Social Anxiety Disorder Unmet Needs

10. Key Endpoints of Social Anxiety Disorder Treatment

11. Social Anxiety Disorder Marketed Therapies

12. Social Anxiety Disorder Emerging Drugs and Latest Therapeutic Advances

13. Social Anxiety Disorder Seven Major Market Analysis

14. Attribute Analysis

15. Social Anxiety Disorder Market Outlook (In US, EU5, and Japan)

16. Social Anxiety Disorder Companies Active in the Market

17. Social Anxiety Disorder Access and Reimbursement Overview

18. KOL Views on the Social Anxiety Disorder Market

19. Social Anxiety Disorder Market Drivers

20. Social Anxiety Disorder Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/social-anxiety-disorder-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

Follicular Lymphoma Market

“Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Follicular Lymphoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Follicular Lymphoma market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Social Anxiety Disorder Market to Accelerate Substantially During the Forecast Period (2023-2032) – DelveInsight | Key Companies – Vistagen Therapeutics, Bionomics, EmpowerPharm

Lyme Disease Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Valneva, Cortene, Tarsus Pharma, Inovio, Aegis Life, Abzyme, Pfizer, Moderna

“Delveinsight Business Research LLP”

DelveInsight’s “Lyme Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Lyme Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Lyme Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Lyme Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Lyme Disease: An Overview

Lyme disease (LD) is primarily caused by the spirochete Borrelia burgdorferi, which enters the bloodstream through the bite of an infected tick after the tick has been attached for 48–72 hours. It stands as the most prevalent vector-borne illness. The way it manifests clinically varies depending on the stage of the disease, encompassing symptoms such as erythema migrans, carditis, central nervous system complications, and arthritis. Irrespective of the particular clinical presentation, the majority of Lyme Disease patients experience a resolution of their symptoms when they receive the appropriate antimicrobial treatment. Persistent symptoms after treatment typically result more from misdiagnosis rather than a failure of the treatment itself.

Randomized controlled trials have ascertained the efficiency of antibiotics in treating erythema migrans, the hallmark of early-stage Lyme borreliosis. Oral amoxicillin and doxycycline are first-line treatment options, though phenoxymethylpenicillin, cefuroxime axetil, and azithromycin are alternative second-line options. Treatments for secondary and tertiary Lyme borreliosis are more poorly documented, and antibiotics are not always effective. Pinpointing the absence of any reliable method of diagnosis, it is difficult to choose the proper treatment and to evaluate treatment efficacy.

However, numerous studies have shown that ceftriaxone and doxycycline are the most efficient antibiotics, particularly in Lyme arthritis and neuroborreliosis. In late Lyme borreliosis, these antibiotics were less efficient, and different treatment schemes with variations in dosage or duration did not produce convincing results.

Lyme Disease Market Key Facts

According to Mead (2015), Lyme disease has been a nationally notifiable condition in the United States since 1991. Case definitions are revised periodically, as in 1996 to clarify laboratory criteria and again in 2008 to allow reporting of probable cases.
As per the Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), and Division of Vector-Borne Diseases (DVBD), recent estimates using other methods suggest that approximately 476,000 people may get Lyme disease each year in the United States.
As per the United States Environmental Protection Agency, the incidence of Lyme disease in the United States has nearly doubled since 1991, from 3.74 reported cases per 100,000 people to 7.21 reported cases per 100,000 people in 2018.

Lyme Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Lyme Disease pipeline therapies. It also thoroughly assesses the Lyme Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Lyme Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Lyme Disease Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Lyme Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Lyme Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Lyme Disease Epidemiology, Segmented as –

Total incident population of Lyme disease
Gender-specific incidence of Lyme disease
Total diagnosed population of Lyme disease
Acute and chronic incidence of Lyme disease
Age-specific diagnosed incidence of Lyme disease

Lyme Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Lyme Disease market or expected to be launched during the study period. The analysis covers the Lyme Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Lyme Disease drugs based on their sale and market share.

The report also covers the Lyme Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Lyme Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Lyme Disease Market Will Evolve and Grow by 2032 @

https://www.delveinsight.com/sample-request/lyme-disease-ld-market

Lyme Disease Therapeutics Analysis

The treatment of Lyme disease varies according to the clinical stage. For each stage, the pathophysiology differs, and therefore the antibiotherapy has to be adapted to the clinical signs. Recently published guidelines and recommendations follow this strategy, in order to help choose the best antibiotics for each clinical situation.

There are no vaccines currently being marketed for Lyme disease. There is now a greater demand for Lyme disease vaccines. This is due to the rise in infections in the US and Europe, arising from factors such as climate change. Alongside predominant dive in prevention by various leading names, Moderna’s recent interest in the condition raises the prospect of additional prophylactic options over the longer term.

Several major pharma and biotech companies are developing therapies for Lyme Disease. Currently, Valneva is leading the therapeutics market with its Lyme Disease drug candidates in the most advanced stage of clinical development.

Lyme Disease Companies Actively Working in the Therapeutics Market Include

To improve the treatment scenario, some of the key companies such as Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, Pfizer, Moderna, and others are actively working in the Lyme Disease Market.

Emerging and Marketed Lyme Disease Therapies Covered in the Report Include:

CT38: Cortene
VLA-15: Valneva/Pfizer
TP-05: Tarsus Pharmaceuticals Inc.
mRNA-1982 and mRNA-1975: Moderna

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/lyme-disease-ld-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Lyme Disease Competitive Intelligence Analysis

4. Lyme Disease Market Overview at a Glance

5. Lyme Disease Disease Background and Overview

6. Lyme Disease Patient Journey

7. Lyme Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Lyme Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Lyme Disease Unmet Needs

10. Key Endpoints of Lyme Disease Treatment

11. Lyme Disease Marketed Therapies

12. Lyme Disease Emerging Drugs and Latest Therapeutic Advances

13. Lyme Disease Seven Major Market Analysis

14. Attribute Analysis

15. Lyme Disease Market Outlook (In US, EU5, and Japan)

16. Lyme Disease Companies Active in the Market

17. Lyme Disease Access and Reimbursement Overview

18. KOL Views on the Lyme Disease Market

19. Lyme Disease Market Drivers

20. Lyme Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/lyme-disease-ld-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

Lichen Planus Market

“Lichen Planus Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lichen Planus market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Lichen Planus market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lyme Disease Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Valneva, Cortene, Tarsus Pharma, Inovio, Aegis Life, Abzyme, Pfizer, Moderna

Friedreich’s Ataxia Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032) – DelveInsight | AavantiBio, Exicure, Lacerta, LEXEO, Minoryx, Reata, Retrotope, StrideBio

“Delveinsight Business Research LLP”

DelveInsight’s “Friedreich’s Ataxia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Friedreich’s Ataxia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Friedreich’s Ataxia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Friedreich’s Ataxia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Friedreich’s Ataxia: An Overview

Friedreich ataxia (also called FA) is a rare inherited disease that causes progressive nervous system damage and movement problems. It usually begins in childhood and leads to impaired muscle coordination (ataxia) that worsens over time.

It is caused due to a defect (mutation) in a gene labeled FXN, which carries the genetic code for a protein called frataxin. Therefore, individuals who inherit two defective copies of the gene, one from each parent, will develop the disease. FA is characterized by two subtypes, LOFA and VLOFA. For LOFA, the age of onset is between the ages of 26 and 39 years, and for VLOFA, the age of onset is after the age of 40 years.

The symptoms typically begin between the ages of 5 and 15 years. Usually, the first neurological symptom is difficulty walking and poor balance. Another early sign of the disease is slowness and slurring of speech (dysarthria). With time speech becomes hesitant and jerky (often referred to as “scanning of speech”). The difficulty coordinating movement (ataxia) can affect all of the muscles. It gradually worsens and slowly spreads to the arms and the trunk (torso).

Diagnosis of Friedreich’s ataxia requires a careful clinical examination, that includes a thorough physical exam, looking for balance difficulty, loss of joint sensation (proprioception), absence of reflexes, and signs of neurological problems. Moreover, genetic testing now provides a conclusive diagnosis.

Friedreich’s Ataxia Market Key Facts

According to the National Institute of Neurological Disorders and Stroke, Friedreich ataxia is the most common form of hereditary ataxia in the US, affecting about 1 in every 50,000 people.
As per the statistics by the National Institute of Neurological Disorders and Stroke, although rare, FA is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. Adult or late-onset FA is less common, <25% of diagnosed individuals, and can occur anytime during adulthood.
According to the study by Jörg S et al. (2009), Friedreich ataxia is the most frequent hereditary ataxia, with an estimated prevalence of 3–4 cases per 100,000 individuals.

Friedreich’s Ataxia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Friedreich’s Ataxia pipeline therapies. It also thoroughly assesses the Friedreich’s Ataxia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Friedreich’s Ataxia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Friedreich’s Ataxia Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Friedreich’s Ataxia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Friedreich’s Ataxia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Friedreich’s Ataxia Epidemiology, Segmented as –

Total Prevalent Cases of Friedreich’s Ataxia [2019–2032]
Diagnosed and Treatable Population of Friedreich’s Ataxia [2019–2032]
Prevalence of Friedreich’s Ataxia based on onset types [2019–2032]

Friedreich’s Ataxia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in Friedreich’s Ataxia market or expected to be launched during the study period. The analysis covers Friedreich’s Ataxia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Friedreich’s Ataxia drugs based on their sale and market share.

The report also covers Friedreich’s Ataxia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Friedreich’s Ataxia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Friedreich’s Ataxia Market Will Evolve and Grow by 2032 @

https://www.delveinsight.com/sample-request/friedreichs-ataxia-market

Friedreich’s Ataxia Therapeutics Analysis

Several major pharma and biotech giants are actively working in Friedreich’s Ataxia Market. Currently, Retrotope is leading the therapeutics market with its Friedreich’s Ataxia drug candidates in the most advanced stage of clinical development.

On February 28, 2023, Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced that the U.S. Food and Drug Administration (“FDA”) had approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older. With this approval, the FDA granted a rare pediatric disease priority review voucher.

Friedreich’s Ataxia Companies Actively Working in the Therapeutics Market Include

AavantiBio
Design Therapeutics
Exicure
Lacerta Therapeutics
Larimar Therapeutics
LEXEO Therapeutics
Metro International Biotech
Minoryx Therapeutics
PTC Therapeutics
Reata Pharmaceuticals
Retrotope
StrideBio
Voyager Therapeutics

And Many Others

Emerging and Marketed Friedreich’s Ataxia Therapies Covered in the Report Include:

CTI-1601: Larimar Therapeutics
FXN gene therapy: AavantiBio
Leriglitazone: Minoryx Therapeutics
MIB-626: Metro International Biotech
Omaveloxolone: Reata Pharmaceuticals
RT001: Retrotope
SynTEFs: Design Therapeutics
Vatiquinone: PTC Therapeutics

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/friedreichs-ataxia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Friedreich’s Ataxia Competitive Intelligence Analysis

4. Friedreich’s Ataxia Market Overview at a Glance

5. Friedreich’s Ataxia Disease Background and Overview

6. Friedreich’s Ataxia Patient Journey

7. Friedreich’s Ataxia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Friedreich’s Ataxia Treatment Algorithm, Current Treatment, and Medical Practices

9. Friedreich’s Ataxia Unmet Needs

10. Key Endpoints of Friedreich’s Ataxia Treatment

11. Friedreich’s Ataxia Marketed Therapies

12. Friedreich’s Ataxia Emerging Drugs and Latest Therapeutic Advances

13. Friedreich’s Ataxia Seven Major Market Analysis

14. Attribute Analysis

15. Friedreich’s Ataxia Market Outlook (In US, EU5, and Japan)

16. Friedreich’s Ataxia Companies Active in the Market

17. Friedreich’s Ataxia Access and Reimbursement Overview

18. KOL Views on the Friedreich’s Ataxia Market

19. Friedreich’s Ataxia Market Drivers

20. Friedreich’s Ataxia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/friedreichs-ataxia-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

IgG4-Related Disease Market

“IgG4-Related Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the IgG4-Related Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the IgG4-Related Disease market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Friedreich\’s Ataxia Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032) – DelveInsight | AavantiBio, Exicure, Lacerta, LEXEO, Minoryx, Reata, Retrotope, StrideBio

Short Bowel Syndrome (SBS) Market to Observe Stupendous Growth During the Study Period (2020-2034) – DelveInsight | 9 Meters Biopharma, Surrozen, Takeda, Adocia, VectivBio, Zealand Pharma, Hanmi Pharma

“Delveinsight Business Research LLP”

The Short Bowel Syndrome Market is set to register immense growth in the coming years owing to the increasing prevalence of SBS and the launch of new therapies in the market. Key players, such as Zealand Pharma, PhaseBio Pharmaceuticals, VectivBio, and several others, are involved in developing therapies for treating SBS patients.

DelveInsight’s “Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Short Bowel Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Short Bowel Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current Short Bowel Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Short Bowel Syndrome: An Overview

Short Bowel Syndrome is a congenital or acquired condition affecting the small intestine, hallmarked by loss of intestinal absorptive capacity with resultant malabsorption, dehydration, and malnutrition. This is due to the loss of absorptive surface area, as the human intestinal tract requires a massive surface area to absorb nutrients to support a growing and living organism effectively.

Short Bowel Syndrome is a challenging condition associated with significant morbidity and mortality, reduced quality of life, and high health care costs. In patients with Short Bowel Syndrome who are receiving long-term home parenteral nutrition (PN), 2–5 years survival rates have been reported to be up to 80% and 70%, respectively. Factors affecting survival with Short Bowel Syndrome include the anatomy and function of the remaining bowel, the patient’s age, the primary disease process, comorbid diseases, the presence of chronic intestinal obstruction, and the experience of the management team.

Short Bowel Syndrome Market Key Facts

The market size of Short Bowel Syndrome in the seven major markets was USD 1720.5 million in 2020, and the market is estimated to increase at a CAGR of 5.82% for the study period (2018–2030).
The total 7MM prevalent cases of Short Bowel Syndrome were 34,713 cases in 2020.
As per the data published by the Crohn’s & Colitis Foundation of America, approximately 10,000–20,000 people suffer from Short Bowel Syndrome in the United States.
As per the study conducted by Websky et al., titled “Short bowel syndrome in Germany. Estimated prevalence and standard of care”, the prevalence of SBS in Germany is 34 per million inhabitants.
According to the American Pediatric Surgical Association, the most common cause of SBS in infants and babies is necrotizing enterocolitis (NEC) which accounts for up to 40% of SBS patients.
According to the European Medicines Agency, SBS affects not more than 0.35 in 10,000 people in the European Union (EU).
As per the data published in PINNT, It is estimated that up to 1,000 people in England have short bowel syndrome, requiring long-term treatment with parenteral nutrition support.

Short Bowel Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Short Bowel Syndrome pipeline therapies. It also thoroughly assesses the Short Bowel Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Short Bowel Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Short Bowel Syndrome Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Short Bowel Syndrome epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted Short Bowel Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Short Bowel Syndrome Epidemiology, Segmented as –

Total Prevalent Cases of Short Bowel Syndrome in the 7MM
Diagnosed and Treatable Cases of Short Bowel Syndrome in the 7MM

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Short Bowel Syndrome market or expected to be launched during the study period. The analysis covers the Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Short Bowel Syndrome drugs based on their sale and market share.

The report also covers the Short Bowel Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Short Bowel Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Short Bowel Syndrome Market Will Evolve and Grow In the Upcoming Years @

https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

Short Bowel Syndrome Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Short Bowel Syndrome. Currently, Zealand Pharma is leading the therapeutics market with its Short Bowel Syndrome drug candidates in the most advanced stage of clinical development.

Short Bowel Syndrome Companies Actively Working in the Therapeutics Market Include

9 Meters Biopharma
Adocia
Hanmi Pharmaceutical
NorthSea Therapeutics
PhaseBio Pharmaceuticals
Surrozen
Takeda
VectivBio AG
Zealand Pharma

And many others

Emerging and Marketed Short Bowel Syndrome Therapies Covered in the Report Include:

Glepaglutide: Zealand Pharma
Gattex (teduglutide): NPS Pharmaceuticals (Acquired by Shire Plc.)
Apraglutide: VectivBio/Therachon AG
NM 002: 9 Meters Biopharma

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Short Bowel Syndrome Competitive Intelligence Analysis

4. Short Bowel Syndrome Market Overview at a Glance

5. Short Bowel Syndrome Disease Background and Overview

6. Short Bowel Syndrome Patient Journey

7. Short Bowel Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Short Bowel Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Short Bowel Syndrome Unmet Needs

10. Key Endpoints of Short Bowel Syndrome Treatment

11. Short Bowel Syndrome Marketed Therapies

12. Short Bowel Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Short Bowel Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Short Bowel Syndrome Market Outlook (In US, EU5, and Japan)

16. Short Bowel Syndrome Companies Active in the Market

17. Short Bowel Syndrome Access and Reimbursement Overview

18. KOL Views on the Short Bowel Syndrome Market

19. Short Bowel Syndrome Market Drivers

20. Short Bowel Syndrome Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

Hidradenitis Suppurativa Market

“Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hidradenitis Suppurativa market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Short Bowel Syndrome (SBS) Market to Observe Stupendous Growth During the Study Period (2020-2034) – DelveInsight | 9 Meters Biopharma, Surrozen, Takeda, Adocia, VectivBio, Zealand Pharma, Hanmi Pharma

Leber Hereditary Optic Neuropathy Market to Observe Impressive Growth During the Forecast Period (2023-2032) – DelveInsight | GenSight Biologics, Neuroptika, Mitotech, Fortify Therapeutics, Neurophth

“Delveinsight Business Research LLP”

As per DelveInsight, the Leber Hereditary Optic Neuropathy Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Leber Hereditary Optic Neuropathy and the launch of new therapies such as GS010 (GenSight) and Elamipretide (Stealth Biotherapeutics) in the market.

DelveInsight’s “Leber Hereditary Optic Neuropathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Leber Hereditary Optic Neuropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Leber Hereditary Optic Neuropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Leber Hereditary Optic Neuropathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Leber Hereditary Optic Neuropathy: An Overview

Leber Hereditary Optic Neuropathy (LHON) manifests as bilateral, painless, and gradual central vision impairment typically striking individuals in their early adulthood. Initially, symptoms often appear in one eye before affecting the other eye a few weeks later. Although uncommon, some cases may present additional neurological manifestations such as peripheral neuropathy, postural tremors, nonspecific myopathy, and movement disorders.

The underlying cause of LHON lies in mutations within mitochondrial DNA, with inheritance occurring exclusively through maternal lines. The incidence of visual impairment due to LHON stands at approximately 1:50,000 individuals. Interestingly, many carriers of the mutation remain asymptomatic throughout their lives, with males exhibiting a notably higher risk of vision loss compared to females, at a ratio of about four to five times. Typically, symptoms emerge during the early adult years, and if vision loss occurs, it usually transpires before the age of 40.

The acute phase of LHON is characterized by central vision loss, presenting symptoms like blurring and diminished color perception. Usually, one eye is affected initially, followed by the other eye within a span of two to three months. Subsequently, the atrophic phase ensues, marked by bilateral optic atrophy leading to permanent blindness.

LHON is diagnosed based on ophthalmologic findings, which include specialized visual testing. The testing involves dilated fundus examination to identify characteristic changes in the optic disc and vascular changes during the acute phase, visual fields, electrophysiologic studies, and imaging, particularly OCT. Molecular genetic testing for mitochondrial genes associated with LHON can be used to confirm diagnosis.

Leber Hereditary Optic Neuropathy Market Key Facts

According to Shemesh et al. (2022), Leber’s hereditary optic neuropathy (LHON) is estimated to be the most frequent mitochondrial disease with a prevalence ranging from 1 in 27,000 in North East England to 1 in 45,000 in a meta-analysis of reports in the European population. It has a strong male preponderance (80% to 90%), and the usual age at onset is between 15 and 35 years.
As per the NORD (2019), the prevalence of visual loss from LHON is approximately 1:50,000 people. Many carriers never suffer significant visual loss; males are about four to five times more likely than females to lose vision and be affected.
As per Man et al. (2016), LHON is characterized by a marked gender bias, with males more likely to become affected than females.
According to a national epidemiological survey on LHON conducted by Takano et al. (2022) in Japan, the number of newly diagnosed patients with LHON in 2019 was estimated to be 69, and the total number of LHON patients in Japan was estimated to be 2400, with a prevalence similar to other countries.

Leber Hereditary Optic Neuropathy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Leber Hereditary Optic Neuropathy pipeline therapies. It also thoroughly assesses the Leber Hereditary Optic Neuropathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Leber Hereditary Optic Neuropathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Leber Hereditary Optic Neuropathy Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Leber Hereditary Optic Neuropathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Leber Hereditary Optic Neuropathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Leber Hereditary Optic Neuropathy Epidemiology, Segmented as –

Total Prevalent Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)
Diagnosed Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)
Gender-specific Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)
Mutation-specific Cases of Leber’s Hereditary Optic Neuropathy (LHON) in the 7MM (2019–2032)

Leber Hereditary Optic Neuropathy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Leber Hereditary Optic Neuropathy market or expected to be launched during the study period. The analysis covers the Leber Hereditary Optic Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Leber Hereditary Optic Neuropathy drugs based on their sale and market share.

The report also covers the Leber Hereditary Optic Neuropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Leber Hereditary Optic Neuropathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Leber Hereditary Optic Neuropathy Market Will Evolve and Grow by 2032 @

https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market

Leber Hereditary Optic Neuropathy Therapeutics Analysis

Currently, Raxone (idebenone) is the only available medicinal product authorized to treat LHON within the European Union. Brimonidine, nutritional supplements, and ubiquinone analogs are the potential treatment options. Along with these therapies, alternative therapies such as steroids and immunosuppressants such as cyclosporine A are being tried in the treatment of LHON. Currently, the most exciting potential means of treating LHON are within the field of gene therapy.

To further improve the treatment scenario, several leading companies are actively engaged in the development of treatments for Leber’s hereditary optic neuropathy (LHON). Among these, GenSight Biologics stands out with its LHON drug candidates, which are currently in the most advanced stage of development, namely the preregistration phase. This signifies a significant milestone in the journey towards providing effective therapies for individuals affected by LHON, highlighting the dedication and progress within the pharmaceutical industry to address this genetic disorder.

Leber Hereditary Optic Neuropathy Companies Actively Working in the Therapeutics Market Include

Several prominent companies are actively engaged in the development of therapies for Leber’s hereditary optic neuropathy (LHON). These companies include GenSight Biologics, which stands out with its LHON drug candidates currently in the most advanced stage of development. Additionally, Neurophth Therapeutics, Mitotech, Stealth BioTherapeutics, Fortify Therapeutics, and Neuroptika are also among the front-runners in this endeavor. Their collective efforts underscore the commitment and progress within the pharmaceutical industry to address LHON, a genetic disorder impacting individuals worldwide.

Emerging and Marketed Leber Hereditary Optic Neuropathy Therapies Covered in the Report Include:

GS010 (lenadogene nolparvovec): GenSight
Elamipretide: Stealth Biotherapeutics
NFS-02: Neurophth Therapeutics
Elamipretide: Stealth BioTherapeutics Inc.

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Leber Hereditary Optic Neuropathy Competitive Intelligence Analysis

4. Leber Hereditary Optic Neuropathy Market Overview at a Glance

5. Leber Hereditary Optic Neuropathy Disease Background and Overview

6. Leber Hereditary Optic Neuropathy Patient Journey

7. Leber Hereditary Optic Neuropathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Leber Hereditary Optic Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Leber Hereditary Optic Neuropathy Unmet Needs

10. Key Endpoints of Leber Hereditary Optic Neuropathy Treatment

11. Leber Hereditary Optic Neuropathy Marketed Therapies

12. Leber Hereditary Optic Neuropathy Emerging Drugs and Latest Therapeutic Advances

13. Leber Hereditary Optic Neuropathy Seven Major Market Analysis

14. Attribute Analysis

15. Leber Hereditary Optic Neuropathy Market Outlook (In US, EU5, and Japan)

16. Leber Hereditary Optic Neuropathy Companies Active in the Market

17. Leber Hereditary Optic Neuropathy Access and Reimbursement Overview

18. KOL Views on the Leber Hereditary Optic Neuropathy Market

19. Leber Hereditary Optic Neuropathy Market Drivers

20. Leber Hereditary Optic Neuropathy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

Meniere’s Disease Market

“Meniere’s Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Meniere’s Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Meniere’s Disease market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leber Hereditary Optic Neuropathy Market to Observe Impressive Growth During the Forecast Period (2023-2032) – DelveInsight | GenSight Biologics, Neuroptika, Mitotech, Fortify Therapeutics, Neurophth

Thyroid Eye Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Viridian Therapeutics, Immunovant Sciences, Horizon Therapeutics

“Delveinsight Business Research LLP”

DelveInsight’s “Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Thyroid Eye Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Thyroid Eye Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Thyroid Eye Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Thyroid Eye Disease: An Overview

Thyroid Eye Disease (TED) is a complex orbital inflammatory disease, that can be sight-threatening, debilitating, and disfiguring. TED is also known as Graves’ ophthalmopathy, named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goiter, rapid heartbeat, and exophthalmos.

TED affects eye muscles, eyelids, tear glands and fatty tissues behind the eye become inflamed. This can cause the eyes and eyelids to become red, swollen, and uncomfortable and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes)

Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations.

Companies all over 7MM are persistently working towards the development of novel treatment therapies that can address Thyroid eye disease. There are several promising drugs in the pipeline including VRDN—001 (Viridian Therapeutics), Secukinumab (Novartis), and IMVT-1401 (Immunovant Sciences GmbH) among others. VRDN-001 is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).

Thyroid Eye Disease Market Key Facts

According to NORD, the exact prevalence (i.e. the number of people who have a disorder in a specific population at a specific time) of Thyroid Eye Disease is not known but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population.
The total prevalent cases of Thyroid Eye Disease in the United States were around 1,012,000 cases in 2022.
The US contributed to the largest prevalent population of Thyroid Eye Disease, acquiring ~42% of the 7MM in 2022. Whereas Germany accounted for around 13% and Japan accounted for around 8% of the total population share, respectively, in 2022.
Among EU4 countries, Germany accounted for the largest number of Thyroid Eye Disease cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
According to DelveInsight estimates, there were around 16,300 cases of acute Thyroid Eye Disease and 41,900 cases of chronic Thyroid Eye Disease in Japan in 2022. These cases are projected to increase during the forecasted period.
In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from Thyroid Eye Disease.

Thyroid Eye Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Thyroid Eye Disease pipeline therapies. It also thoroughly assesses the Thyroid Eye Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Thyroid Eye Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Thyroid Eye Disease Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted Thyroid Eye Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Thyroid Eye Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Thyroid Eye Disease Epidemiology, Segmented as –

Prevalent Cases of Thyroid Eye Disease
Diagnosed Prevalent Cases of Thyroid Eye Disease
Gender-specific Diagnosed Prevalent Cases of Thyroid Eye Disease
Diagnosed Prevalent Cases of Thyroid Eye Disease
Moderate-to-severe Drug-treated Cases of Acute Thyroid Eye Disease

Thyroid Eye Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Thyroid Eye Disease market or expected to be launched during the study period. The analysis covers the Thyroid Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Thyroid Eye Disease drugs based on their sale and market share.

The report also covers the Thyroid Eye Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Thyroid Eye Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Thyroid Eye Disease Market Will Evolve and Grow by 2032 @

https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market

Thyroid Eye Disease Therapeutics Analysis

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Thyroid Eye Disease. Currently, Novartis is leading the therapeutics market with its Thyroid Eye Disease drug candidates in the most advanced stage of clinical development.

Thyroid Eye Disease Companies Actively Working in the Therapeutics Market Include

Novartis
Viridian Therapeutics
Immunovant Sciences GmbH
Horizon Therapeutics

And Many Others

Emerging and Marketed Thyroid Eye Disease Therapies Covered in the Report Include:

Secukinumab (Novartis)
VRDN-001 (Viridian Therapeutics)
IMVT-1401 (Immunovant Sciences GmbH)

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Thyroid Eye Disease Competitive Intelligence Analysis

4. Thyroid Eye Disease Market Overview at a Glance

5. Thyroid Eye Disease Disease Background and Overview

6. Thyroid Eye Disease Patient Journey

7. Thyroid Eye Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Thyroid Eye Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Thyroid Eye Disease Unmet Needs

10. Key Endpoints of Thyroid Eye Disease Treatment

11. Thyroid Eye Disease Marketed Therapies

12. Thyroid Eye Disease Emerging Drugs and Latest Therapeutic Advances

13. Thyroid Eye Disease Seven Major Market Analysis

14. Attribute Analysis

15. Thyroid Eye Disease Market Outlook (In US, EU5, and Japan)

16. Thyroid Eye Disease Companies Active in the Market

17. Thyroid Eye Disease Access and Reimbursement Overview

18. KOL Views on the Thyroid Eye Disease Market

19. Thyroid Eye Disease Market Drivers

20. Thyroid Eye Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market

About DelveInsight

Other Trending Healthcare Reports by DelveInsight

Retinal Vein Occlusion Market

“Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Retinal Vein Occlusion market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Retinal Vein Occlusion market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thyroid Eye Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Viridian Therapeutics, Immunovant Sciences, Horizon Therapeutics

Desmoid Tumors Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharma, Iterion Therapeutics

“Desmoid Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Desmoid Tumors, historical and forecasted epidemiology as well as the Desmoid Tumors market trends in the 7MM.

DelveInsight’s “Desmoid Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Desmoid Tumors, historical and forecasted epidemiology as well as the Desmoid Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Desmoid Tumors market outook, drug uptake, treatment scenario and epidemiology trends, Click here; Desmoid Tumors Marklet Forecast

Some of the key facts of the Desmoid Tumors Market Report:

The Desmoid Tumors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Approximately 65% of the diagnosed cases are either stable or being actively monitored for spontaneous regression. About 9,000 cases in the US will either be stable in 2022 or will be actively monitored for spontaneous regression
Around 14,000 desmoid tumour cases were reported in the US overall in 2022, and that number is expected to rise somewhat more by 2032 than it did in 2022. According to DelveInsight projections, the US region with the highest prevalence of desmoid tumour patients was the 7MM
Desmoid tumours make up 0.03% of all tumours, according to data from The Desmoid Tumour Research Foundation and the National Organisation for Rare Disorders (NORD). Five to six cases per million persons are thought to occur in the general community each year
Less than 3% of all soft-tissue tumours are desmoid tumours, according to the American Society of Clinical Oncology (ASCO). In the United States, 900 to 1,500 persons are given a desmoid tumour diagnosis each year. Although it can happen at any age, this form of tumour primarily affects persons between the ages of 15 and 60
Desmoid tumours are linked to CTNNB1 mutations in more than 75% of cases, according to a study by Kumar et al. published in 2021 and titled “Desmoid tumour and molecular testing from patient reported data in an international natural history study.”
Key Desmoid Tumors Companies: Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc., and others
Key Desmoid Tumors Therapies: Sirolimus, Imatinib, Nirogacestat, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others
The Desmoid Tumors epidemiology based on gender analyzed that Desmoid Tumors are more common in women as compared to men
The Desmoid Tumors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Desmoid Tumors pipeline products will significantly revolutionize the Desmoid Tumors market dynamics.

Desmoid Tumors Overview

Desmoid tumours (DT), which form in connective tissue, are benign growths. Because of their resemblance to the dangerous tumour fibrosarcoma, they are sometimes known as aggressive fibromatosis. Because it does not metastasize—or spread—to other bodily parts, it is regarded as benign.

Get a Free sample for the Desmoid Tumors Market Report

https://www.delveinsight.com/report-store/desmoid-tumors-market

Desmoid Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Desmoid Tumors Epidemiology Segmentation:

The Desmoid Tumors market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Desmoid Tumors
Prevalent Cases of Desmoid Tumors by severity
Gender-specific Prevalence of Desmoid Tumors
Diagnosed Cases of Episodic and Chronic Desmoid Tumors

Download the report to understand which factors are driving Desmoid Tumors epidemiology trends @ Desmoid Tumors Epidemiology Forecast

Desmoid Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Desmoid Tumors market or expected to get launched during the study period. The analysis covers Desmoid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Desmoid Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Desmoid Tumors Therapies and Key Companies

Nirogacestat: SpringWorks Therapeutics
AL102: Ayala Pharmaceuticals
Tegavivint: Iterion Therapeutics
Sirolimus: Pfizer
Imatinib: Novartis
Nab-Rapamycin: Aadi Bioscience, Inc.
Fentanyl sublingual spray: INSYS Therapeutics Inc
REC-4881: Recursion Pharmaceuticals Inc.

Discover more about therapies set to grab major Desmoid Tumors market share @ Desmoid Tumors Treatment Market

Desmoid Tumors Market Drivers

Desmoid Tumors is a rare form of cancer; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.

Desmoid Tumors Market Barriers

Lack of approved therapies indicate an opportune time to invest in research and development as the Desmoid Tumors therapy segment is currently being explored by only a handful of players.

Scope of the Desmoid Tumors Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Desmoid Tumors Companies: Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc., and others
Key Desmoid Tumors Therapies: Sirolimus, Imatinib, Nirogacestat, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others
Desmoid Tumors Therapeutic Assessment: Desmoid Tumors current marketed and Desmoid Tumors emerging therapies
Desmoid Tumors Market Dynamics: Desmoid Tumors market drivers and Desmoid Tumors market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Desmoid Tumors Unmet Needs, KOL’s views, Analyst’s views, Desmoid Tumors Market Access and Reimbursement

To know more about Desmoid Tumors companies working in the treatment market, visit @ Desmoid Tumors Clinical Trials and Therapeutic Assessment

Table of Contents

1. Desmoid Tumors Market Report Introduction

2. Executive Summary for Desmoid Tumors

3. SWOT analysis of Desmoid Tumors

4. Desmoid Tumors Patient Share (%) Overview at a Glance

5. Desmoid Tumors Market Overview at a Glance

6. Desmoid Tumors Disease Background and Overview

7. Desmoid Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Desmoid Tumors

9. Desmoid Tumors Current Treatment and Medical Practices

10. Desmoid Tumors Unmet Needs

11. Desmoid Tumors Emerging Therapies

12. Desmoid Tumors Market Outlook

13. Country-Wise Desmoid Tumors Market Analysis (2019–2032)

14. Desmoid Tumors Market Access and Reimbursement of Therapies

15. Desmoid Tumors Market Drivers

16. Desmoid Tumors Market Barriers

17. Desmoid Tumors Appendix

18. Desmoid Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Desmoid Tumors Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharma, Iterion Therapeutics